• SIS3 (Smad3 Inhibitor): Precision Modulation of TGF-β Signal

  2026-06-20

  Discover how SIS3, a selective Smad3 inhibitor, enables advanced control of TGF-β signaling for fibrosis and diabetic nephropathy research. This article uniquely bridges mechanistic insight from cancer epigenetics with practical assay recommendations, offering a deeper perspective on SIS3’s applications.

• ML385: Applied NRF2 Inhibition for Cancer and Ferroptosis Re

  2026-06-19

  ML385 is redefining NRF2 signaling pathway inhibition in cancer and neurodegeneration studies, enabling researchers to dissect therapeutic resistance, oxidative stress, and ferroptosis with precision. This guide translates the latest in vivo evidence and practical workflows into actionable protocols and troubleshooting strategies for leveraging ML385's unique properties.

• Gut-Brain Cholinergic Signaling in Seizure Suppression by B.

  2026-06-19

  Jia et al. reveal that Bacteroides fragilis suppresses seizures through activation of a gut-vagus-brain cholinergic pathway, mediated by colonic ChAT+ cells and associated with increased Lactobacillus colonization. These mechanistic insights advance the understanding of microbiota-driven neural circuits and support the development of targeted microbiota therapies for pediatric refractory epilepsy.

• Mubritinib (TAK 165) Interaction with Human Serum Albumin: M

  2026-06-18

  This study investigates how Mubritinib (TAK 165), a mitochondrial complex I inhibitor, interacts with human serum albumin (HSA), revealing detailed binding characteristics and functional consequences. These findings inform the pharmacokinetics and bioavailability of Mubritinib, which are critical for its development in cancer and metabolic disease research.

• Phase Separation of FUS and PARylated PARP1: Cation and PAR

  2026-06-18

  This study characterizes how polyamines, divalent metal cations, and the structural features of poly(ADP-ribose) (PAR) regulate the phase separation of FUS with PARylated PARP1. The findings advance understanding of nuclear condensate assembly during DNA damage response, with implications for future cancer research and selective PARP inhibitor applications.

• ORM2-ZG16 Axis Regulates Pancreatic Fibrosis via Autophagy C

  2026-06-17

  This study uncovers ORM2 as a critical suppressor of pancreatic fibrosis in chronic pancreatitis, acting through ZG16-mediated inhibition of autophagy in pancreatic stellate cells. The findings reveal a mechanistic link between acute-phase proteins and fibrogenesis, offering new targets for pancreatic function research.

• Mubritinib Enhances Cisplatin Efficacy in NSCLC via Mitochon

  2026-06-17

  This study demonstrates that Mubritinib (TAK 165), traditionally viewed as a HER2 pathway inhibitor, enhances cisplatin's antitumor activity in non-small cell lung cancer (NSCLC) by targeting mitochondrial function. The findings highlight a mitochondria-centered mechanism, offering new avenues for overcoming cisplatin resistance in lung cancer.

• Olive Oil Polyphenols: Antioxidant and Anti-Inflammatory Mec

  2026-06-16

  This study systematically dissects the antioxidant, anti-inflammatory, and anti-atherogenic activities of extra virgin olive oil (EVOO) polyphenols, highlighting the strategic importance of polyphenol concentration and the distinct roles of compounds like hydroxytyrosol. The findings offer mechanistic insight into how EVOO polyphenols modulate cardiovascular risk pathways, with practical implications for experimental design in cardiovascular research.

• ERAD-Hijacking Chimeras Unlock Transmembrane Protein Degrada

  2026-06-16

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that leverages the ER-associated degradation pathway to selectively degrade transmembrane proteins. This technology addresses a longstanding barrier in targeted protein degradation, enabling efficient elimination of membrane targets and expanding possibilities for both basic research and therapeutic development.

• UTP Solution (100 mM): Enabling Precision in Epigenetic RNA

  2026-06-15

  This thought-leadership article explores how APExBIO’s UTP Solution (100 mM) empowers translational researchers tackling epigenetic regulation of gene expression, with a special focus on monogenic olfactory receptor choice. We bridge mechanistic insight, protocol rigor, and strategic guidance to escalate the RNA research paradigm beyond standard product discussions.

• Sodium Ascorbate: Protocols and Advances in Cancer Research

  2026-06-15

  Sodium Ascorbate, a mineral salt of ascorbic acid, delivers unique protocol flexibility and robust induction of intracellular ROS for advanced tumor models. Explore optimized workflows, troubleshooting, and the latest comparative insights for glioblastoma and beyond.

• BMX-IN-1: BMX Kinase Inhibitor for Precision Cell Assays

  2026-06-14

  BMX-IN-1, a highly selective BMX kinase inhibitor from APExBIO, empowers researchers to dissect kinase-driven signaling in cancer and host-pathogen models with unrivaled specificity. This guide delivers actionable protocols and troubleshooting strategies, highlighting BMX-IN-1’s unique impact on apoptosis, cell cycle arrest, and lysosomal regulation in translational research.

• Ibrexafungerp’s In Vitro Efficacy Against Echinocandin-Resis

  2026-06-13

  This study systematically evaluates ibrexafungerp (MK 3118) activity against a large, well-characterized cohort of echinocandin-resistant Candida isolates using both phenotypic and genotypic analyses. The findings reveal species- and mutation-dependent susceptibility patterns, underscoring ibrexafungerp's potential for overcoming certain resistance mechanisms in invasive candidiasis.

• HyperScript™ Reverse Transcriptase for Robust cDNA Synthesis

  2026-06-12

  HyperScript™ Reverse Transcriptase empowers researchers to overcome RNA secondary structure barriers and detect low copy RNA in advanced qPCR workflows. Its exceptional thermal stability and reduced RNase H activity set a new benchmark for reliable, high-fidelity cDNA synthesis in transcriptomic applications.

• ERAD-Hijacking Chimeras Enable Degradation of Transmembrane

  2026-06-12

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a transformative approach that enables efficient, selective degradation of transmembrane proteins by hijacking the endoplasmic reticulum-associated degradation (ERAD) pathway. This methodology overcomes a key obstacle for targeted protein degradation, expanding the scope for therapeutic and mechanistic research.

452 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page